FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006978204> ?p ?o ?g. }

• W2006978204 abstract "Abstract Background As schizophrenia patients are typically suspicious of, or are hostile to changes they may be reluctant to accept generic substitution, possibly affecting compliance. This may counteract drug costs savings due to less symptom control and increased hospitalization risk. Although compliance losses following generic substitution have not been quantified so far, one can estimate the possible health-economic consequences. The current study aims to do so by considering the case of risperidone in Germany. Methods An existing DES model was adapted to compare staying on branded risperidone with generic substitution. Differences include the probability of non-compliance and medication costs. Incremental probability of non-compliance after generic substitution was varied between 2.5% and 10%, while generic medication costs were assumed to be 40% lower. Effect of medication price was assessed as well as the effect of applying compliance losses to all treatment settings. The probability of staying on branded risperidone being cost-effective was calculated for various outcomes of a hypothetical study that would investigate non-compliance following generic substitution of risperidone. Results If the incremental probability of non-compliance after generic substitution is 2.5%, 5.0%, 7.5% and 10% respectively, incremental effects of staying on branded risperidone are 0.004, 0.007, 0.011 and 0.015 Quality Adjusted Life Years (QALYs). Incremental costs are €757, €343, -€123 and -€554 respectively. Benefits of staying on branded risperidone include improved symptom control and fewer hospitalizations. If generic substitution results in a 5.2% higher probability of non-compliance, the model predicts staying on branded risperidone to be cost-effective (NICE threshold of ₤30,000 per QALY gained). Compliance losses of more than 6.9% makes branded risperidone the dominant alternative. Results are sensitive to the locations at which compliance loss is applied and the price of generic risperidone. The probability that staying on branded risperidone is cost-effective would increase with larger compliance differences and more patients included in the hypothetical study. Conclusion The model predicts that it is cost-effective to keep a patient with schizophrenia in Germany on branded risperidone instead of switching him/her to generic risperidone (assuming a 40% reduction in medication costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5.2%." @default.
• W2006978204 created "2016-06-24" @default.
• W2006978204 creator A5028354821 @default.
• W2006978204 creator A5032690231 @default.
• W2006978204 creator A5039014104 @default.
• W2006978204 creator A5039926945 @default.
• W2006978204 creator A5048074724 @default.
• W2006978204 date "2009-02-18" @default.
• W2006978204 modified "2023-10-18" @default.
• W2006978204 title "A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss" @default.
• W2006978204 cites W1486406930 @default.
• W2006978204 cites W181307884 @default.
• W2006978204 cites W192004289 @default.
• W2006978204 cites W1972850098 @default.
• W2006978204 cites W1976542298 @default.
• W2006978204 cites W2000796170 @default.
• W2006978204 cites W2003756370 @default.
• W2006978204 cites W2012541603 @default.
• W2006978204 cites W2013672598 @default.
• W2006978204 cites W2042571708 @default.
• W2006978204 cites W2057492103 @default.
• W2006978204 cites W2069024810 @default.
• W2006978204 cites W2070893229 @default.
• W2006978204 cites W2088044851 @default.
• W2006978204 cites W2093965133 @default.
• W2006978204 cites W2095976945 @default.
• W2006978204 cites W2096635847 @default.
• W2006978204 cites W2098395209 @default.
• W2006978204 cites W2109070861 @default.
• W2006978204 cites W2122522597 @default.
• W2006978204 cites W2126234298 @default.
• W2006978204 cites W2128438886 @default.
• W2006978204 cites W2138418531 @default.
• W2006978204 cites W2143189599 @default.
• W2006978204 cites W2144234230 @default.
• W2006978204 doi "https://doi.org/10.1186/1472-6963-9-32" @default.
• W2006978204 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2652458" @default.
• W2006978204 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19226465" @default.
• W2006978204 hasPublicationYear "2009" @default.
• W2006978204 type Work @default.
• W2006978204 sameAs 2006978204 @default.
• W2006978204 citedByCount "26" @default.
• W2006978204 countsByYear W20069782042012 @default.
• W2006978204 countsByYear W20069782042013 @default.
• W2006978204 countsByYear W20069782042014 @default.
• W2006978204 countsByYear W20069782042015 @default.
• W2006978204 countsByYear W20069782042016 @default.
• W2006978204 countsByYear W20069782042017 @default.
• W2006978204 countsByYear W20069782042018 @default.
• W2006978204 countsByYear W20069782042020 @default.
• W2006978204 countsByYear W20069782042021 @default.
• W2006978204 crossrefType "journal-article" @default.
• W2006978204 hasAuthorship W2006978204A5028354821 @default.
• W2006978204 hasAuthorship W2006978204A5032690231 @default.
• W2006978204 hasAuthorship W2006978204A5039014104 @default.
• W2006978204 hasAuthorship W2006978204A5039926945 @default.
• W2006978204 hasAuthorship W2006978204A5048074724 @default.
• W2006978204 hasBestOaLocation W20069782041 @default.
• W2006978204 hasConcept C118552586 @default.
• W2006978204 hasConcept C137992405 @default.
• W2006978204 hasConcept C138816342 @default.
• W2006978204 hasConcept C15744967 @default.
• W2006978204 hasConcept C159110408 @default.
• W2006978204 hasConcept C199360897 @default.
• W2006978204 hasConcept C2776412080 @default.
• W2006978204 hasConcept C2778220771 @default.
• W2006978204 hasConcept C2780057945 @default.
• W2006978204 hasConcept C2781460075 @default.
• W2006978204 hasConcept C41008148 @default.
• W2006978204 hasConcept C71924100 @default.
• W2006978204 hasConcept C77805123 @default.
• W2006978204 hasConceptScore W2006978204C118552586 @default.
• W2006978204 hasConceptScore W2006978204C137992405 @default.
• W2006978204 hasConceptScore W2006978204C138816342 @default.
• W2006978204 hasConceptScore W2006978204C15744967 @default.
• W2006978204 hasConceptScore W2006978204C159110408 @default.
• W2006978204 hasConceptScore W2006978204C199360897 @default.
• W2006978204 hasConceptScore W2006978204C2776412080 @default.
• W2006978204 hasConceptScore W2006978204C2778220771 @default.
• W2006978204 hasConceptScore W2006978204C2780057945 @default.
• W2006978204 hasConceptScore W2006978204C2781460075 @default.
• W2006978204 hasConceptScore W2006978204C41008148 @default.
• W2006978204 hasConceptScore W2006978204C71924100 @default.
• W2006978204 hasConceptScore W2006978204C77805123 @default.
• W2006978204 hasIssue "1" @default.
• W2006978204 hasLocation W20069782041 @default.
• W2006978204 hasLocation W20069782042 @default.
• W2006978204 hasLocation W20069782043 @default.
• W2006978204 hasLocation W20069782044 @default.
• W2006978204 hasLocation W20069782045 @default.
• W2006978204 hasLocation W20069782046 @default.
• W2006978204 hasOpenAccess W2006978204 @default.
• W2006978204 hasPrimaryLocation W20069782041 @default.
• W2006978204 hasRelatedWork W1969891922 @default.
• W2006978204 hasRelatedWork W2021147513 @default.
• W2006978204 hasRelatedWork W2050162510 @default.
• W2006978204 hasRelatedWork W2068802033 @default.
• W2006978204 hasRelatedWork W2118787204 @default.
• W2006978204 hasRelatedWork W2379257132 @default.
• W2006978204 hasRelatedWork W2884007892 @default.

• next